Rivastigmine (sold among others under the trade name Exelon) is a cholinesterase inhibitor used to treat mild to moderate Alzheimer's and Parkinson's disease. The medication can be administered orally or via a transdermal patch; the latter type decreases the severity of side effects, usually including nausea and vomiting. Rivastigmine capsules, liquid solution, and patches are used to treat mild to moderate Alzheimer-type dementia, and mild to moderate Parkinson-related dementia. Rivastigmine has been shown to provide meaningful symptomatic effects in people with either type of dementia, which can allow patients to remain independent and 'be themselves' for longer. In particular, there appear to be marked effects of treatment in patients with a more aggressive course of disease, such as those with a younger age, poor nutritional status, or those with symptoms.
Letter to Editor: Journal of Brain Research
Letter to Editor: Journal of Brain Research
Editorial: Journal of Brain Research
Editorial: Journal of Brain Research
Research Article: Journal of Brain Research
Research Article: Journal of Brain Research
Research Article: Journal of Brain Research
Research Article: Journal of Brain Research
Case Report: Journal of Brain Research
Case Report: Journal of Brain Research
Posters & Accepted Abstracts: Cancer Science & Therapy
Posters & Accepted Abstracts: Cancer Science & Therapy
Posters: Cancer Science & Therapy
Posters: Cancer Science & Therapy
Scientific Tracks Abstracts: Alternative & Integrative Medicine
Scientific Tracks Abstracts: Alternative & Integrative Medicine
Posters & Accepted Abstracts: Journal of Nephrology & Therapeutics
Posters & Accepted Abstracts: Journal of Nephrology & Therapeutics
Journal of Brain Research received 2 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 